PPIs vs H2RAs for erosive reflux esophagitis.
King
V J
VJ
University of North Carolina, Chapel Hill, USA. vking@med.unc.edu
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000208:Acute Disease; D003362:Cost-Benefit Analysis; D004791:Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000191:economics / Q000517:prevention & control*; D006635:Histamine H2 Antagonists / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D064747:Lansoprazole; D008390:Markov Chains; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D011899:Ranitidine / Q000191:economics / Q000627:therapeutic use*; D012008:Recurrence; D015203:Reproducibility of Results
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D064747:Lansoprazole; D011899:Ranitidine; D009853:Omeprazole